相关实验视频
Updated: Jan 15, 2026

10:22
Humanized Mediator Release Assay as a Read-Out for Allergen Potency
Published on: June 29, 2021
3.9K
用于被动过敏免疫疗法的过敏特异性人类单克隆IgG抗体
Scott A Smith1,2, Cosby A Stone3, Alain Jacquet4
1Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
概括
使用阻断IgG抗体的被动过敏免疫疗法 (PAIT) 为传统的过敏原特异性免疫疗法 (AIT) 提供了一个有希望的替代方案. 这种方法证明了在减少过敏反应的安全性和有效性,可能更少的管理.
科学领域:
- 免疫学 免疫学 免疫学
- 过敏学 过敏学
- 生物技术是生物技术.
背景情况:
- 诸如鼻炎,喘,皮肤炎和食物过敏等过敏性疾病在全球范围内正在增加.
- 目前的过敏原特异性免疫疗法 (AIT) 有局限性,包括长时间的治疗,副作用和患者不良服药.
- 由AIT诱导的阻断IgG抗体对于长期免疫耐受性至关重要.
研究的目的:
- 审查使用单克隆阻断抗体的被动过敏免疫疗法 (PAIT) 的临床前和临床数据.
- 评估PAIT作为传统AIT的潜在更安全,更有效的替代品.
- 为突出生产人类单克隆抗体用于过敏治疗的进展.
主要方法:
- 对PAIT进行的临床前和临床研究的审查.
- 专注于针对特定过敏原IgE表位体的抗体尾酒.
- 利用单克隆抗体生产的进步和罕见的B细胞隔离.
主要成果:
- 作为一种安全有效的方法,PAIT显示出降低过敏反应的潜力.
- 与传统的AIT相比,PAIT可能需要少得多的剂量.
- 单克隆抗体技术使得人类抗体的产生具有高度亲和力,以目标过敏原.
结论:
- PAIT代表了传统AIT的优雅替代品,可能改善患者的遵守性.
- 抗体工程的技术进步促进了针对性过敏治疗的开发.
- 需要对PAIT进行进一步的临床研究,以确定其充分的治疗潜力.
相关概念视频
Antibody Structure
65.3K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
65.3K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Cross-reactivity
32.8K
Overview
32.8K
Allergic Reactions
32.0K
Overview
32.0K
Allergic Drug Reactions
1.3K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.3K
Hybridoma Technology
17.3K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
17.3K

